Calcium ions in neuronal degeneration

IUBMB Life

Volumn 60, Issue 9, 2008, Pages 575-590

  Wojda, Urszula ^a   Salinska, Elzbieta ^b   Kuznicki, Jacek ^a,c  

^a INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Autosomal dominant spinocerebellar ataxias; Brain stroke; Ca2+ homeostasis; Ca2+ signaling; Epilepsy; Glaucoma; HIV dementia; Huntington's disease; Parkinson's disease; Schizophrenia; Traumatic brain injury

Indexed keywords

CALCIUM ION; GLUTAMATE RECEPTOR; VOLTAGE GATED CALCIUM CHANNEL; CALCIUM; CALCIUM CHANNEL;

AGING; AMYOTROPHIC LATERAL SCLEROSIS; CALCIUM CELL LEVEL; CALCIUM DEPLETION; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; DEMENTIA; DISEASE ASSOCIATION; EPILEPSY; GLAUCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUNTINGTON CHOREA; ION CURRENT; NERVE CELL; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION; STROKE; TRAUMATIC BRAIN INJURY; ANIMAL; DEGENERATIVE DISEASE; HOMEOSTASIS; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; CALCIUM; CALCIUM CHANNELS; CALCIUM SIGNALING; HOMEOSTASIS; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEURONS; RECEPTORS, GLUTAMATE;

EID: 56149105398     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.91     Document Type: Review

References (184)

1. Berridge, M. J., Bootman, M. D., and Roderick, H. L. (2003) Calcium signalling: dynamics, homeostasis and remodeling. Nat. Rev. Mol. Cell Biol. 4, 517-529.
2. Feske, S. (2007) Calcium signalling in lymphocyte activation and disease. Nat. Rev. Immunol. 9, 690-702.
3. Ghosh, A. and Greenberg, M. E. (1995) Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science 268, 239-247.
4. Berridge, M. J., Lipp, P., and Bootman, M. D. (2000) The versatility and universality of calcium signaling. Nat. Rev. Mol. Cell Biol. 1, 11-21.
5. Berridge, M. J. (1998) Neuronal calcium signaling. Neuron 21, 13-26.
6. Augustine, G. J., Santamaria, F., and Tanaka, K. (2003) Local calcium signaling in neurons. Neuron 40, 331-346.
7. Rao, V. R. and Finkbeiner, S. (2007) NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci. 30, 284-291.
8. Köhr, G. (2006) NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 326, 439-446. (Pubitemid 44435819)
9. Lohmann, C. and Wong, R. O. (2005) Regulation of dendritic growth and plasticity by local and global calcium dynamics. Cell Calcium 37, 403-409. (Pubitemid 40458436)
10. Bear, M., Connors, B. W., and Paradiso, M. A. (2001) Neuroscience, Exploring the Brain. Lippincott Williams & Wilkins, Baltimore.
11. + buffers and synaptic efficacy. Cell Calcium 37, 489-495.
12. Beresewicz, M., Kowalczyk, J. E., and Zablocka, B. (2006) Cytochrome c binds to inositol (1,4,5) trisphosphate and ryanodine receptors invivo after transient brain ischemia in gerbils. Neurochem. Int. 48, 568-571.
13. Putney, J. W. (2005) Capacitative calcium entry: sensing the calcium stores. J. Cell Biol. 169, 381-382.
14. + levels. Cell 131, 1327-1339.
15. Hewavitharana, T., Deng, X., Soboloff, J., and Gill, D. L. (2007) Role of STIM and Orai proteins in the store-operated calcium signaling pathway. Cell Calcium 42, 173-182. (Pubitemid 47029604)
16. Kretsinger, R. H. (1997) EF-hands embrace. Nat. Struct. Biol. 4, 514-516.
17. +-binding helix-loop-helix EF-hand motifs. Biochem. J. 405, 199-221.
18. Lewit-Bentley, A. and Réty, S. (2000) EF-hand calcium-binding proteins. Curr. Opin. Struct. Biol. 10, 637-643.
19. + signaling. Nat. Rev. Neurosci. 8, 182-193.
20. Haeseleer, F., Imanishi, Y., Sokal, I., Filipek, S., and Palczewski, K. (2002) Calcium-binding proteins: intracellular sensors from the calmodulin superfamily. Biochem. Biophys. Res. Commun. 290, 615-623.
21. Bhattacharya, S., Bunick, C. G., and Chazin, W. J. (2004) Target selectivity in EF-hand calcium binding proteins. Biochim. Biophys. Acta. 1742, 69-79.
22. Grabarek, Z. (2005) Structure of a trapped intermediate of calmodulin: calcium regulation of EF hand proteins from a new perspective. J. Mol. Biol. 346, 1351-1366
23. Ames, J. B., Ishima, R., Tanaka, T., Gordon, J. I., Stryer, L., and Ikura, M. (1997) Molecular mechanics of calcium-myristoyl switches. Nature 389, 198-202.
24. +-dependent translocation of the calcyclin-binding protein in neurons and neuroblastoma NB-2a cells. J. Biol. Chem. 277, 21103-21109.
25. +)-dependent transcription. Curr. Opin. Neurobiol. 11, 312-319.
26. Gomes, D. A., Leite, M. F., Bennett, A. M., and Nathanson, M. H. (2006) Calcium signaling in the nucleus. Can. J. Physiol. Pharmacol. 84, 325-332.
27. + clearance from neurons. Front. Biosci. 7, 1255-1279.
28. 2+ Buffers, Handbook of Cell Signaling. Elsevier Science, USA.
29. +-handling proteins. J. Cell Biol. 160, 475-479.
30. +) signals. J. Biol. Chem. 276, 26411-26420.
31. + as a key regulator of cell life and heath. Cell Death Differ. 14, 1267-1274.
32. Chinopoulos, C. and Adam-Vizi, V. (2006) Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J. 273, 433-450.
33. Glabe, C. G. and Kayed, R. (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, 74-78.
34. Mattson, M. P. (2007) Calcium and neurodegeneration. Aging Cell 6, 337-350.
35. Salinska, E., Danysz, W., and Lazarewicz, J. W. (2005) The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 43, 322-339.
36. Takuma, K., Yan, S. S., Stern, D. M., and Yamada, K. (2005) Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J. Pharmacol. Sci. 97, 312-316.
37. Bano, D. and Nicotera, P. (2007) Ca2+ signals and neuronal death in brain ischemia. Stroke 38, 674-676. (Pubitemid 46184239)
38. Toescu, E. C. and Verkhratsky, A. (2007) The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell 6, 267-273.
39. Murchison, D. and Griffith, W. H. (2007) Calcium buffering systems and calcium signaling in aged rat basal forebrain neurons. Aging Cell 6, 297-305. (Pubitemid 46785135)
40. Erickson, C. A. and Barnes, C. A. (2003) The neurobiology of memory changes in normal aging. Exp. Gerontol. 38, 61-69.
41. Nicholson, D. A., Yoshida, R., Berry, R. W., Gallagher, M., and Geinisman, Y. (2004) Reduction in size of perforated postsynaptic densities in hippocampal axospinous synapses and age- related spatial learning impairments. J. Neurosci. 24, 7648-7653. (Pubitemid 39186819)
42. Gibson, G. E. and Peterson, C. (1987) Calcium and the aging nervous system. Neurobiol. Aging 8, 329-343.
43. Landfield, P. W. (1987) Increased calcium-current' hypothesis of brain aging. Neurobiol. Aging 8, 346-347.
44. Khachaturian, Z. S. (1994) Calcium hypothesis of Alzheimer's disease and brain aging. Ann. N. Y. Acad. Sci. 747, 1-11.
45. Foster, T. C. (2007) Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 6, 319-325.
46. Thibault, O., Gant, J. C., and Landfield, P. W. (2007) Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 6, 307-317. (Pubitemid 46785136)
47. + homeostasis in peripheral neurones: implications for changes in function. Aging Cell 6, 285-296.
48. Bu, J., Sathyendra, V., Nagykery, N., and Geula, C. (2003) Age-related changes in calbindin-D28k, calretinin, and parvalbumin-immunoreactive neurons in the human cerebral cortex. Exp. Neurol. 182, 220-231.
49. Esin, M. M. (2007) Ageing and the brain. J. Pathol. 211, 181-187.
50. Mattson, M. P. (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. (Pubitemid 39061671)
51. Selkoe, D. J. (2004) Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140, 627-638
52. Hardy, J. and Gwinn-Hardy, K. (1998) Genetic classification of primary neurodegenerative disease. Science 282, 1075-1079. (Pubitemid 28516229)
53. De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., and Van Leuven, F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390. (Pubitemid 28093512)
54. Murray, F. E., Landsberg, J. P., Williams, R. J., Esiri, M. M., and Watt, F. (1992) Elemental analysis of neurofibrillary tangles in Alzheimer's disease using proton-induced X-ray analysis. Ciba Found. Symp. 169, 201-210.
55. Nixon, R. A., Saito, K. I., Grynspan, F., Griffin, W. R., Katayama, S., Honda, T., Mohan, P. S., Shea, T. B., and Beermann, M. (1994) Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann. N. Y. Acad. Sci. 747, 77-91.
56. Mattson, M. P. and Chan, S. L. (2001) Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J. Mol. Neurosci. 2, 205-224.
57. LaFerla, F. M. (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3, 862-872.
58. Smith, I. F., Green, K. N., and LaFerla, F. M. (2005) Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium 38, 427-437.
59. Stutzmann, G. E. (2007) The pathogenesis of Alzheimers disease - is it a lifelong "calciumopathy"? Neuroscientist 13, 546-559.
60. Bojarski, L., Herms, J., and Kuznicki, J. (2008) Calcium dysregulation in Alzheimer's disease. Neurochem. Int. 52, 621-633.
61. Mattson, M. P., Engle, M. G., and Rychlik, B. (1991) Effects of elevated intracellular calcium levels on the cytoskeleton and tau in cultured human cortical neurons. Mol. Chem. Neuropathol. 15, 117-142.
62. Pierrot, N., Santos, S. F., Feyt, C., Morel, M., Brion, J. P., and Octave, J. N. (2006) Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-β accumulation. J. Biol. Chem. 281, 39907-39914.
63. Querfurth, H. W. and Selkoe, D. J. (1994) Calcium ionophore increases amyloid β Alzheimer's disease. Nat. Rev. Neurosci. 3, 862-872.
64. Buxbaum, J. D., Ruefli, A. A., Parker, C. A., Cypess, A. M., and Greengard, P. (1994) Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. USA 91, 4489-4493.
65. Pierrot, N., Ghisdal, P., Caumont, A. S., and Octave, J. N. (2004) Intraneuronal amyloid-β1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J. Neurochem. 5, 1140-1150. (Pubitemid 38280681)
66. Kawahara, M. and Kuroda, Y. (2000) Molecular mechanism of neuro-degeneration induced by Alzheimer's β-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res. Bull. 4, 389-397.
67. Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., and Greengard, P. (2005) Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 8, 1051-1058.
68. Leissring, M. A., Murphy, M. P., Mead, T. R., Akbari, Y., Sugarman, M. C., Jannatipour, M., Anliker, B., Muller, U., Saftig, P., De Strooper, B., Wolfe, M. S., Golde, T. E., and LaFerla, F. M. (2002) A physiologic signaling role for the γ secretase-derived intracellular fragment of APP. Proc. Natl. Acad. Sci. USA 99, 4697-4702.
69. Hamid, R., Kilger, E., Willem, M., Vassallo, N., Kostka, M., Bornhövd, C., Reichert, A. S., Kretzschmar, H. A., Haass, C., and Herms, J. (2007) Amyloid precursor protein intracellular domain modulates cellular calcium homeostasis and ATP content. J. Neurochem. 4, 1264-1275. (Pubitemid 47174237)
70. Leissring, M. A., Parker, I., and LaFerla, F. M. (1999) Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate- mediated calcium signals. J. Biol. Chem. 274, 32535-32538.
71. Pack-Chung, E., Meyers, M. B., Pettingell, W. P., Moir, R. D., Brownawell, A. M., Cheng, I., Tanzi, R. E., and Kim, T. W. (2000) Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor. J. Biol. Chem. 275, 14440-14445.
72. Chan, S. L., Mayne, M., Holden, C. P., Geiger, J. D., and Mattson, M. P. (2000) Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 275, 18195-18200.
73. + disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 26, 5180-5189.
74. Priller, C., Dewachter, I., Vassallo, N., Pace, C., Kretzschmar, H., Van Leuven, F., and Herms, J. (2006) Mutant Presenilin 1 alters synaptic transmisson in cultured hippocampal neurons. J. Biol. Chem. 282, 1119-1127.
75. Leissring, M. A., Akbari, Y., Fanger, C. M., Cahalan, M. D., Mattson, M. P., and LaFerla, F. M. (2000) Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149, 793-798. (Pubitemid 30327232)
76. Yoo, A. S., Cheng, I., Chung, S., Grenfell, T. Z., Lee, H., Pack-Chung, E., Handler, M., Shen, J., Xia, W., Tesco, G., Saunders, A. J., Ding, K., Frosch, M. P., Tanzi, R. E., and Kim, T. W. (2000) Presenilin-mediated modulation of capacitative calcium entry. Neuron 27, 561-572.
77. + leak function of presenilin 1. J. Clin. Invest. 5, 1230-1239.
78. Buxbaum, J. D., Choi, E. K., Luo, Y., Lilliehook, C., Crowley, A. C., Merriam, D. E., and Wasco, W. (1998) Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat. Med. 4, 1177-1181.
79. Jin, J. K., Choi, J. K., Wasco, W., Buxbaum, J. D., Kozlowski, P. B., Carp, R. I., Kim, Y. S., and Choi, E. K. (2005) Expression of calsenilin in neurons and astrocytes in the Alzheimer's disease brain. Neuroreport 5, 451-455. (Pubitemid 40477547)
80. Stabler, S. M., Ostrowski, L. L., Janicki, S. M., and Monteiro, M. J. (1999) A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer's disease presenilin 2 protein. J. Cell Biol. 145, 1277-1292.
81. Bernstein, H. G., Blazejczyk, M., Rudka, T., Gundelfinger, E. D., Dobrowolny, H., Bogerts, B., Kreutz, M. R., Kuznicki, J., and Wojda, U. (2005) The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal aging brains. Neuropathol. Appl. Neurosci. 31, 314-324.
82. +-signals to Alzheimer's disease-related presenilin 2 in forebrain. Biochim. Biophys. Acta. 1762, 66-72.
83. Thomas, B. and Beal, M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 2, 183-194.
84. Yamada, T., McGeer, P. L., Baimbridge, K. G., and McGeer, E. G. (1990) Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 2, 303-307.
85. Mouatt-Prigent, A., Agid, Y., and Hirsch, E. C. (1994) Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res. 1-2, 62-70.
86. Kim, B. G., Shin, D. H., Jeon, G. S., Seo, J. H., Kim, Y. W., Jeon, B. S., and Cho, S. S. (2000) Relative sparing of calretinin containing neurons in the substantia nigra of 6-OHDA treated rat Parkinsonian model. Brain Res. 1, 162-165.
87. Soós, J., Engelhardt, J. I., Siklós, L., Havas, L., and Majtényi, K. (2004) The expression of PARP, NF-κ B and parvalbumin is increased in Parkinson disease. Neuroreport 11, 1715-1718.
88. Tamamizu-Kato, S., Kosaraju, M. G., Kato, H., Raussens, V., Ruysschaert, J. M., and Narayanaswami, V. (2006) Calcium-triggered membrane interaction of the a-synuclein acidic tail. Biochemistry 36, 10947-10956.
89. + influx through voltage-dependent Ca2+ channels. Neuroreport 17, 1883-1886.
90. Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., and Kostka, M. (2007) Different species of α-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220-9232.
91. Facheris, M., Beretta, S., and Ferrarese, C. (2004) Peripheral markers of oxidative stress and excitotoxicity in neurodegenerative disorders: tools for diagnosis and therapy? J. Alzheimers Dis. 6, 177-184.
92. Surmeier, D. J. (2007) Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 6, 933-938.
93. Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., and Surmeier, D. J. (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447, 1081-1086.
94. Chade, A. R., Kasten, M., and Tanner, C. M. (2006) Nongenetic causes of Parkinson's disease. J. Neural Transm.Suppl. 70, 147-151.
95. Mrak, R. E. and Griffin, W. S. (2007) Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J. Neuropathol. Exp. Neurol. 66, 683-686.
96. Abou-Sleiman, P. M., Muqit, M. M., and Wood, N. W. (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7, 207-219.
97. Lindholm, D., Wootz, H., and Korhonen, L. (2006) ER stress and neurodegenerative diseases. Cell Death Differ. 13, 385-392.
98. Ramaswamy, S., Shannon, K. M., and Kordower, J. H. (2007) Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant. 16, 301-312.
99. Nakamura, K. and Aminoff, M. J. (2007) Huntington's disease: clinical characteristics, pathogenesis and therapies. Drugs Today (Barc). 43, 97-116.
100. Bezprozvanny, I. and Hayden, M. R. (2004) Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310-1317.
101. Gutekunst, C. A., Li, S. H., Yi, H., Ferrante, R. J., Li, X. J., and Hersch, S. M. (1998) The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J. Neurosci. 18, 7674-7686.
102. Panov, A. V., Gutekunst, C. A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., and Greenamyre, J. T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736.
103. Tang, T. S., Tu, H., Chan, E. Y., Maximov, A., Wang, Z., Wellington, C. L., Hayden, M. R., and Bezprozvanny, I. (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39, 227-239.
104. Mao, L. and Wang, J. Q. (2001) Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons. Brain Res. Mol. Brain Res. 86, 125-137.
105. Mao, L. and Wang, J. Q. (2002) Glutamate cascade to cAMP response element-binding protein phosphorylation in cultured striatal neurons through calcium-coupled group I metabotropic glutamate receptors. Mol. Pharmacol. 62, 473-484.
106. Tallaksen-Greene, S. J., Kaatz, K. W., Romano, C., and Albin, R. L. (1998) Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res. 780, 210-217.
107. Fan, M. M. and Raymond, L. A. (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 81, 272-293.
108. Sun, Y., Savanenin, A., Reddy, P. H., and Liu, Y. F. (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713-24718.
109. Ali, D. W. and Salter, M. W. (2001) NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity. Curr. Opin. Neurobiol. 11, 336-342.
110. Song, C., Zhang, Y., Parsons, C. G., and Liu, Y. F. (2003) Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J. Biol. Chem. 278, 33364-33369.
111. Zoghbi, H. Y. (2000) Spinocerebellar ataxias. Neurobiol. Dis. 7, 523-527.
112. Duenas, A. M., Goold, R., and Giunti, P. (2006) Molecular pathogenesis of spinocerebellar ataxias. Brain 129, 1357-1370.
113. Vig, P. J. S., Subramony, S. H., Qin, Z., McDaniel, D. O., and Fratkin, J. D. (2000) Relationship between ataxin-1 nuclear inclusions and Purkinje cell specific proteins in SCA-1 transgenic mice. J. Neurol. Sci. 174, 100-110.
114. Lin, X., Antalffy, B., Kang, D., Orr, H. T., and Zoghbi, H. Y. (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat. Neurosci. 3, 157-163.
115. 2+ channels and channelopathies of the central nervous system. Mol. Neurobiol. 25, 31-50.
116. Quigley, H. A. (1996) Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80, 389-393.
117. Chidlow, G., Wood, J. P., and Casson, R. (2007) Pharmacological neuroprotection for glaucoma. Drugs 67, 725-759.
118. Chung, H. S., Harris, A., Evans, D. W., Kagemann, L., Garzozi, J. H., and Martin, B. (1999) Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv. Ophthalmol. 43, 43-50.
119. Hayreh, S. S., Podhajsky, P., and Zimmerman, M. B. (1999) Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica 213, 76-96. (Pubitemid 29049393)
120. 2+ and sodium blocking activities: relevance to glaucoma. Brain Res. Bull. 62, 525-528.
121. Stys, P. K. (2004) White matter injury mechanisms. Curr. Mol. Med. 4, 113-130.
122. Rowland, L. P. and Shneider, N. A. (2001) Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688-1700.
123. Strong, M. J., Kesavapany, S., and Path, H. C. (2005) The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J. Neuropathol. Exp. Neurol. 64, 649-664.
124. Van Den Bosch, L., Van Damme, P., Bogaert, E., and Robberecht, W. (2006) The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta. 1762, 1068-1082.
125. Ince, P., Stout, N., Shaw, P., Slade, J., Hunziker, W., Heizmann, C. W., and Baimbridge, K. G. (1993) Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol. 19, 291-299.
126. Carriedo, S. G., Yin, H. Z., and Weiss, J. H. (1996) Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. 16, 4069-4079.
127. 2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. 28, 494-500.
128. DeLorenzo, R. J., Sun, D. A., and Deshpan de, L. S. (2005) Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy. Pharmacol. Ther. 105, 229-266.
129. Khosravani, H. and Zamponi, G. W. (2006) Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol. Rev. 86, 941-966.
130. + channels and absence epilepsy. Cell Calcium 40, 191-196.
131. Imbrici, P., Jaffe, S. L., Eunson, L. H., Davies, N. P., Herd, C., Robertson, R., Kullmann, D. M., and Hanna, M. G. (2004) Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. Brain 127, 2682-2692.
132. Perez-Reyes, E. (2006) Molecular characterization of T-type calcium channels. Cell Calcium 40, 89-96.
133. Kim, D., Song, I., Keum, S., Lee, T., Jeong, M. J., Kim, S. S., McEnery, M. W., and Shin, H. S. (2001) Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice. Neuron 31, 35-45.
134. McNamara, J. O., Huang, Y. Z., and Leonard, A. S. (2006) Molecular signaling mechanisms underlying epileptogenesis. Sci. STKE 356, re12.
135. Lewis, D. A. and Moghaddam, B. (2006) Cognitive dysfunction in schizophrenia: convergence of γ-aminobutyric acid and glutamate alterations. Arch. Neurol. 63, 1372-1376.
136. 2+: clinical correlates in affective illness and schizophrenia. Biol. Psychiatry 14, 37-51.
137. 2+ signaling dysfunction in schizophrenia: a unifying approach. Brain Res. Brain Res. Rev. 43, 70-84.
138. Mirnics, K., Middleton, F. A., Stanwood, G. D., Lewis, D. A., and Levitt, P. (2001) Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry. 6, 293-301.
139. Blennow, K., Bogdanovic, N., Gottfries, C. G., and Davidsson, P. (1999) The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia. J. Mol. Neurosci. 13, 101-109.
140. Perrone-Bizzozero, N. I., Sower, A. C., Bird, E. D., Benowitz, L. I., Ivins, K. J., and Neve, R. I. (1996) Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. Natl. Acad. Sci. USA 93, 14182-14187.
141. 2+ in Bcl-2 action? Biochimie 84, 195-201.
142. Jarskog, L. F., Gilmore, J. H., Selinger, E. S., and Liebermann, J. A. (2000) Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry 48, 641-650.
143. Rashid, A. J., So, C. H., Kong, M. M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B. F., and George, S. R. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. USA 104, 654-659.
144. Kristiansen, L. V., Huberta, I., Beneyto, M., and Meador-Woodruff, J. H. (2007) NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7, 48-55.
145. Millan, M. J. (2005) N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl). 179, 30-53.
146. Benes, F. M., Kwok, E. W., Vincent, S. L., and Todtenkopf, M. S. (1998) A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry. 44, 88-97.
147. Falkai, P. and Bogerts, B. (1986) Cell loss in the hippocampus of schizophrenics. Eur. Arch. Psychiatry Neurol. Sci. 236, 154-161.
148. Jennett, B. (1996) Epidemiology of head injury. J. Neurol. Neurosurg. Psychiatry 60, 362-369.
149. 2+ homeostasis following traumatic neuronal injury. Curr. Neurovasc. Res. 1, 151-171.
150. Gennarelii, T. A. and Graham, D. I. (1998) Neuropathology of the Head Injuries. Semin. Clin. Neuropsychiatry 3, 160-175.
151. Graham, D. I., Ford, I., Adams, J. H., Doyle, D., Teasdale, G. M., Lawrence, A. E., and McLellan, D. R. (1989) Ischemic brain damage is still common in fatal non-missile head injury. J. Neurol. Neurosurg. Psychiatry 52, 346-350.
152. 2+ influx modulated by tetrodotoxin-sensitive sodium channels. J. Neurosci. 21, 1923-1930.
153. Pellegrini-Giampietro, D. E., Zukin, R. S., Bennet, M. V., Cho, S., and Pulsinelli, W. A. (1992) Switch in glutamate receptor subunit gene expression in CA1 subfield of hippocampus following global ischemia in rats. Proc. Natl. Acad. Sci. USA 89, 10499-10503.
154. Won, S. J., Kim, D. Y., and Gwag, B. J. (2002) Cellular and molecular pathways of ischemic neuronal death. J. Biochem. Mol. Biol. 35, 67-86.
155. Gentelman, H. E., Lepton, S. A., Tardieu, M., Bukrinsky, M. I., and Nottet, H. S. (1994) The neuropathogenesis of HIV-1 infection. J. Leukoc. Biol. 56, 389-398.
156. Mattson, P. T., Haughey, N. J., and Nath, A. (2005) Cell death in HIV dementia. Cell Death Differ. 12, 893-904.
157. 2+ dysregulation and neuron cell death caused by HIV-1 protein tat. J. Neurochem. 73, 1363-1374.
158. Haughey, N. J., Nath, A., Mattson, M. P., Slevin, J. T., and Geiger, J. D. (2001) HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J. Neurochem. 78, 457-467.
159. Kirby, J., Green, C., Loveman, E., Clegg, A., Picot J., Takeda, A., and Payne, E. (2006) A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging 23, 227-240.
160. Jain, K. K. (2000) Evaluation of memantine for neuroprotection in dementia. Expert Opin. Investig. Drugs 9, 1397-1406.
161. Ahlemeyer, B. and Krieglestein, J. (2003) Neuroprotective effects of Ginkgo biloba extract. Cell Mol. Life Sci. 60, 1779-1792.
162. Muir, K. W. and Lees, K. R. (2003) Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst. Rev. 3, CD001244.
163. Davis, S. M., Lees, K. R., Albers, G. W., Diener, H. C., Markabi, S., Karlsson, G., and Norris, J. (2000) Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist. Stroke 31, 347-354.
164. Lees, K. R., Asplund, K., Carolei, A., Davis, S. M., Diener, H. C., Kaste, M., Orgogozo, J. M., and Whitehead, J. (2000) Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 355, 1949-1954.
165. Hurtado, O., Moro, M. A., Cardenas, A., Sanchez, V., Fernandez-Tome, P., Leza, J. C., Lorenzo, P., Secades, J. J., Lozano, R., Davaloz, A., Castillo, J., and Lizasoain, I. (2005) Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol. Dis. 18, 336-345.
166. Tsai, G. E., Yang, P., Chang, Y. C., and Chong, M. Y. (2006) D-alanine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 59, 230-234.
167. Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., and Ermilov, M. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57, 577-585.
168. Lane, H. Y., Chang, Y. C., Liu, Y. C., Chiu, C. C., and Tsai, G. E. (2005) Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62, 1196-1204.
169. Hurko, O. and Walsh, F. S. (2000) Novel drug development for amyotrophic lateral sclerosis. J. Neurol. Sci. 180, 21-28.
170. Howes, J. F. and Bell, C. (2007) Talampanel. Neurotherapeutics 4, 126-129.
171. Inzitari, D. and Poggesi, A. (2005) Calcium channel blockers and stroke. Aging Clin. Exp. Res. 17(4 Suppl), 16-30.
172. 2+ in human neurons and astrocytes. Neuroscience 91, 1369-1378.
173. Nadia, B. A., Dafni, U., Tucker, T., Singer, E., McArthur, J. C., Yiannoutsos, C., Zaborski, L., and Lepton, S. A. (1998) A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 51, 221-228.
174. Orgul, S., Zawinka, C., Gugleta, K., and Flammer, J. (2005) Strategies for normal-tension glaucoma. Ophthalmologica 219, 317-323.
175. Osborne, N. N., Cassone, R. J., Wood, J. P., Chidlow, G., Graham, M., and Melena, J. (2004) Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 23, 91-147.
176. Gazulla, J. and Tintore, M. (2007) The P/Q-type voltage-dependent Ca
177. Yabe, I., Sasaki, H., Yamashita, I., Takei, A., and Tashiro, K. (2001) Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry. Acta. Neurol. Scand. 104, 44-47.
178. Strupp, M., Zwergal, A., and Brandt, T. (2007) Episodic ataxia type 2. Neurotherapeutics 4, 267-273.
179. Sun, W., Park, K. W., Choe, J., Rhyu, I. J., Kim, I. H., Park, S. K., Choi, B., Choi, S. H., Park, S. H., and Kim, H. (2005) Identification of novel electroconvulsive shock-induced and activity-dependent genes in the rat brain. Biochem. Biophys. Res. Commun. 327, 848-856.
180. Gomora, J. C., Daud, A. N., Weiergräber, M., and Perez-Reyes, E. (2001) Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol. Pharmacol. 60, 1121-1132.
181. 2+)-release from rat brain microsomes. Biol. Psychiatry 40, 497-502.
182. Gnegy, M. E., Agrawal, A., Hewlett, K., Yeung, E., and Yee, S. (1994) Repeated haloperidol increases both calmodulin and a calmodulin-binding protein in rat striatum. Brain Res. Mol. Brain Res. 27, 195-204.
183. Simpkins, J. W., Wang, J., Wang, X., Perez, E., Prokain, L., and Dykens, J. A. (2005) Mitochondria play a central role in estrogen-induced neuroprotection. Curr. Drug Targets CNS Neurol. Disord. 4, 69-83.
184. Wise, P. M., Dubal, D. B., Wilson, M. E., and Rau, S. W. (2000) Estradiol is a neuroprotective factor in in vivo and in vitro models of brain injury J. Neurocytol. 29, 401-410.